<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2125">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05172128</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00108907</org_study_id>
    <nct_id>NCT05172128</nct_id>
  </id_info>
  <brief_title>Effect of Blueberry Supplementation on Alzheimer's Biomarkers</brief_title>
  <official_title>Effect of Blueberry Supplementation on Alzheimer's Biomarkers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>U.S. Highbush Blueberry Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to study the effects of blueberries on neuronal, glial, and&#xD;
      pathology blood biomarkers in Mild Cognitive Impairment (MCI) and to estimate sample size for&#xD;
      future confirmatory studies. The blood biomarkers to be measured are Neurofilament light&#xD;
      (NfL), glial fibrillary acidic protein (GFAP), Aß40, Aß42, p-tau181, and cytokines, using an&#xD;
      ultra-sensitive state-of-the-art immunoassay.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After determining subject eligibility and after subjects have abstained from consuming all&#xD;
      berry fruits (including red wine) for 2 weeks, subjects will have blood drawn for biomarkers&#xD;
      and will then will undergo 12 weeks of blueberry supplementation in the form of 18 grams&#xD;
      lyophilized blueberry powder mixed with water and taken twice daily with meals. All subjects&#xD;
      will be asked to abstain from berry fruits (including red wine) for the duration of the 12&#xD;
      week trial. Subjects will receive telephone calls at 4 and 8 weeks to check compliance as&#xD;
      well as concomitant medications and adverse events and then all subjects will return at 12&#xD;
      weeks for a repeat biomarker blood draw. Plasma NfL, GFAP, Aβ40, Aβ42, p-tau181, and cytokine&#xD;
      biomarker assays will be done using the Quanterix SR-X instrument, a new, state-of-the-art&#xD;
      digital immunoassay platform employing Simoa technology, which enables the detection and&#xD;
      quantification of biomarkers previously difficult or impossible to measure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 21, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in blood Neurofilament light (NfL) levels as measured by blood biomarker assay</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in blood glial fibrillary acidic protein (GFAP) levels as measured by blood biomarker assay</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in blood Amyloid beta 40/42 as measured by blood biomarker assay</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in p-tau 181 as measured by blood biomarker assay</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in blood interleukin-6 (IL-6) levels as measured by blood biomarker assay</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in tumor necrosis factor (TNF-alpha) levels as measured by blood biomarker assay</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Blueberry supplementation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive 18 grams lyophilized blueberry supplement mixed with water twice daily for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>lyophilized blueberry supplement</intervention_name>
    <description>lyophilized blueberry supplement bid</description>
    <arm_group_label>Blueberry supplementation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 55 to 85 years old inclusive&#xD;
&#xD;
          2. Meets criteria for amnestic Mild Cognitive Impairment defined by education adjusted&#xD;
             performance on the Wechsler Memory Scale (WMS) III Logical Memory delayed recall score&#xD;
             and clinical evaluation.&#xD;
&#xD;
          3. Medically stable&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Dementia&#xD;
&#xD;
          2. Significant confounding active neurological/psychiatric disease&#xD;
&#xD;
          3. Participation in an experimental investigational drug trial in the past 30 days&#xD;
&#xD;
          4. Unwilling to restrict consumption of anthocyanin-rich foods&#xD;
&#xD;
          5. Inability to complete cognitive testing (e.g. significant visual or hearing&#xD;
             impairment)&#xD;
&#xD;
          6. Allergy or intolerance to blueberries&#xD;
&#xD;
          7. Significant gastrointestinal disorders or surgery that influences digestion and&#xD;
             absorption&#xD;
&#xD;
          8. Presence of unstable, acutely symptomatic, or life-limiting illness&#xD;
&#xD;
          9. Women of childbearing potential&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Murali Doraiswamy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Caroline A Hellegers, MA</last_name>
    <phone>919-681-3986</phone>
    <email>caroline.hellegers@duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Adaora Nwosu, B.S.</last_name>
    <phone>919-684-5929</phone>
    <email>adaora.nwosu@duke.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>caroline Hellegers, M.A.</last_name>
      <phone>919-681-3986</phone>
      <email>caroline.hellegers@duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Adaora Nwosu, B.S</last_name>
      <phone>919-681-5929</phone>
      <email>adaora.nwosu@duke.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Miller MG, Hamilton DA, Joseph JA, Shukitt-Hale B. Dietary blueberry improves cognition among older adults in a randomized, double-blind, placebo-controlled trial. Eur J Nutr. 2018 Apr;57(3):1169-1180. doi: 10.1007/s00394-017-1400-8. Epub 2017 Mar 10.</citation>
    <PMID>28283823</PMID>
  </reference>
  <reference>
    <citation>Wang S, Cui Y, Wang C, Xie W, Ma L, Zhu J, Zhang Y, Dang R, Wang D, Wu Y, Wu Q. Protective Effects of Dietary Supplementation with a Combination of Nutrients in a Transgenic Mouse Model of Alzheimer's Disease. PLoS One. 2015 Nov 25;10(11):e0143135. doi: 10.1371/journal.pone.0143135. eCollection 2015. Erratum in: PLoS One. 2015;10(12):e0146252. Cu, Yu [corrected to Cui, Yu].</citation>
    <PMID>26606074</PMID>
  </reference>
  <reference>
    <citation>Jeong HR, Jo YN, Jeong JH, Kim HJ, Kim MJ, Heo HJ. Blueberry (Vaccinium virgatum) leaf extracts protect against Aβ-induced cytotoxicity and cognitive impairment. J Med Food. 2013 Nov;16(11):968-76. doi: 10.1089/jmf.2013.2881. Epub 2013 Oct 11.</citation>
    <PMID>24117094</PMID>
  </reference>
  <reference>
    <citation>Brewer GJ, Torricelli JR, Lindsey AL, Kunz EZ, Neuman A, Fisher DR, Joseph JA. Age-related toxicity of amyloid-beta associated with increased pERK and pCREB in primary hippocampal neurons: reversal by blueberry extract. J Nutr Biochem. 2010 Oct;21(10):991-8. doi: 10.1016/j.jnutbio.2009.08.005. Epub 2009 Dec 1.</citation>
    <PMID>19954954</PMID>
  </reference>
  <reference>
    <citation>Ou Y, Hu H, Wang Z, Xu W, Tan L, et al. Plasma neurofilament light as a longitudinal biomarker of neurodegeneration in Alzheimer's disease. Brain Science Advances. 2019;5(2):94-105.</citation>
  </reference>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 9, 2021</study_first_submitted>
  <study_first_submitted_qc>December 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2021</study_first_posted>
  <last_update_submitted>February 21, 2022</last_update_submitted>
  <last_update_submitted_qc>February 21, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MCI</keyword>
  <keyword>biomarkers</keyword>
  <keyword>memory loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

